For one thing, JMJD6 intercepted the transcriptional activity of p53 and increased its association with a p53 negative regulator MDMX by inhibiting p53 acetylation and promoting its hydroxylation (43), which may confer the pro-colon cancer activity of JMJD6. This evidence concerns the gene TP53 and colonic neoplasm.